Innovent Biologics, Inc. | Fifty 1 Labs, Inc.

Innovent Biologics, Inc. (HKEX: 01801), a world-class biopharmaceutical company announced that clinical data of IBI363 (first-in-class PD-1/IL-2 α-bias bispecific antibody fusion protein) in advanced solid tumors are presented at the 2024 ESMO Virtual Plenary. Fifty 1 Labs, Inc. (OTCPK: CAFI), a holding company that operates in the sports supplement, fitness equipment, and health and wellness industries is pleased to provide an update to its shareholders regarding recent strategic initiatives and significant developments within the company. Over the past several months, Fifty 1 Labs has been diligently working behind the scenes to position itself for sustained long-term success and robust growth. For more information, please visit StockDayMedia.com Advertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy